As pharmaceutical companies rely more on sales representatives, reps say they need more training to help them in their jobs.
According to "Sales Rep Training: A Comparative Analysis â 2001," a new strategic study from Newtown, PA-based Scott-Levin, more than 80% of reps find their initial training effective, and 75% say the same for advanced training.
However, 40% of reps think their companies should invest more in training programs, and many also want more hands-on experience. Ninety percent say new-rep training programs include field time with district managers and experienced reps, but 72% say most of their time is spent in the classroom. Sixty-two percent say they would benefit from increased field training.
In addition, 60% of reps want more technology-based instruction, such as CD-ROMs and Web-based training.
The study also found that:
• Reps say the best-trained sales forces are from New York-based Pfizer Inc. and Merck & Co. Inc., Whitehouse Station, NJ.
• Reps from Philadelphia-based Smith-Kline Beecham and Pfizer rate their training as above average, while Parsippany, NJ-based Aventis Pharma AG earns higher-than-average marks for its advanced training.
• The topics most frequently covered for new reps include product knowledge, disease knowledge and management, professional selling skills, and anatomy and physiology.
• Advanced trainees rate professional selling skills as the most popular topic.
The report was based on responses from more than 900 reps from 20 companies. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.